SCHEMBL4936573

SCHEMBL4936573

c1cc(-c2ccc(N3CCC4(CCN(C5CCC5)CC4)C3)nn2)ccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.37
CYP2C9 P11712 5/20 0.36
CYP2C19 P33261 4/20 0.36
MAPK1 P28482 2/20 0.36
ITGB3 P05106 2/20 0.35
ITGA2B P08514 2/20 0.35
KDM2B Q8NHM5 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
CYP3A4 P08684 4/20 0.35
ALDH1A1 P00352 2/20 0.34
CYP2D6 P10635 2/20 0.34
TSHR P16473 2/20 0.34
CYP1A2 P05177 2/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CSNK1E P49674 1/20 0.34
HIF1A Q16665 1/20 0.33
CHRNA7 P36544 1/20 0.33
HTR3A P46098 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4123006 0.94 NPC1 (0.36) CYP2C9CYP2C19MAPK1CSNK1ECHRNA7
SCHEMBL4134856 0.93 CSNK1E (0.37) CYP2C9CYP2C19KDM2BHRH3CYP3A4
SCHEMBL4931859 0.87 SCD (0.42) KCNH2CYP2C9CYP2C19KDM2BHRH3
SCHEMBL4282407 0.82 MAPT (0.47) KDM2BHRH3MEN1KMT2A
SCHEMBL4130690 0.82 CHRNA7 (0.46) HRH3ALDH1A1TSHRCHRNA7HTR3A
SCHEMBL4288681 0.80 SCD (0.50) HRH3MEN1KMT2A
SCHEMBL4136820 0.80 HRH3 (0.37) KCNH2KDM2BHRH3
SCHEMBL4278806 0.80 SCD (0.47) KDM2BHRH3MEN1KMT2A
SCHEMBL4292748 0.80 SCD (0.50) KDM2BHRH3MEN1KMT2A
SCHEMBL4136835 0.80 SCD (0.46) KCNH2CYP2C9CYP2C19KDM2BHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 KCNH2 3110/4885CYP2C9 1705/4885CYP2C19 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.